Leishmaniasis in humans: drug or vaccine therapy?
M Ghorbani, R Farhoudi - Drug design, development and therapy, 2017 - Taylor & Francis
Leishmania is an obligate intracellular pathogen that invades phagocytic host cells.
Approximately 30 different species of Phlebotomine sand flies can transmit this parasite …
Approximately 30 different species of Phlebotomine sand flies can transmit this parasite …
Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review
Chagas disease, leishmaniasis and schistosomiasis are neglected diseases (NDs) and are
a considerable global challenge. Despite the huge number of people infected, NDs do not …
a considerable global challenge. Despite the huge number of people infected, NDs do not …
Insights into the sand fly saliva: Blood-feeding and immune interactions between sand flies, hosts, and Leishmania
T Lestinova, I Rohousova, M Sima… - PLoS neglected …, 2017 - journals.plos.org
Background Leishmaniases are parasitic diseases present worldwide that are transmitted to
the vertebrate host by the bite of an infected sand fly during a blood feeding. Phlebotomine …
the vertebrate host by the bite of an infected sand fly during a blood feeding. Phlebotomine …
Laboratory diagnostics for human Leishmania infections: a polymerase chain reaction-focussed review of detection and identification methods
Leishmania infections span a range of clinical syndromes and impact humans from many
geographic foci, but primarily the world's poorest regions. Transmitted by the bite of a female …
geographic foci, but primarily the world's poorest regions. Transmitted by the bite of a female …
An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy
The azole antifungal drugs are an important class of chemotherapeutic agents with broad-
spectrum of activity against yeasts and filamentous fungi, act in the ergosterol biosynthetic …
spectrum of activity against yeasts and filamentous fungi, act in the ergosterol biosynthetic …
Laboratory diagnosis of human visceral leishmaniasis
H Sakkas, C Gartzonika… - Journal of vector borne …, 2016 - journals.lww.com
Visceral leishmaniasis (VL), caused by the Leishmania donovani complex, is a vector-borne
systemic disease, with a worldwide distribution causing high morbidity and mortality in the …
systemic disease, with a worldwide distribution causing high morbidity and mortality in the …
Leishmaniasis and various immunotherapeutic approaches
Leishmaniasis is a vector-borne infectious disease caused by multiple Leishmania (L.)
species with diverse clinical manifestations. There is currently no vaccine against any form …
species with diverse clinical manifestations. There is currently no vaccine against any form …
[PDF][PDF] 5-year outcomes after coverage of soft tissue dehiscence around single implants: A prospective cohort study
G Zucchelli, P Felice, C Mazzotti, M Marzadori… - European journal of …, 2018 - cris.unibo.it
When citing, please refer to the published version. This is the peer reviewed accepted
manuscript of the following article: Or Page 1 This item was downloaded from IRIS Università di …
manuscript of the following article: Or Page 1 This item was downloaded from IRIS Università di …
In Vitro and In Vivo Effectiveness of Carvacrol, Thymol and Linalool against Leishmania infantum
MR Youssefi, E Moghaddas, MA Tabari… - Molecules, 2019 - mdpi.com
Background: One of the most important causative agents of visceral leishmaniasis (VL) is
Leishmania infantum, which is mainly spread by Phlebotomus and Lutzomyia sandflies in …
Leishmania infantum, which is mainly spread by Phlebotomus and Lutzomyia sandflies in …
Identification of chalcone-based antileishmanial agents targeting trypanothione reductase
All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit
several drawbacks including toxicity, high costs and route of administration. Furthermore …
several drawbacks including toxicity, high costs and route of administration. Furthermore …